Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1215Neoplasms 1024Carcinoma, Non-Small-Cell Lung 747Prostatic Neoplasms 687Colorectal Neoplasms 590Lung Neoplasms 572Pancreatic Neoplasms 394Leukemia, Myeloid, Acute 394Neoplasm Metastasis 387Ovarian Neoplasms 370Multiple Myeloma 369Stomach Neoplasms 316Carcinoma, Hepatocellular 301Melanoma 281Brain Neoplasms 277Recurrence 273Squamous Cell Carcinoma of Head and Neck 267Head and Neck Neoplasms 237Endometrial Neoplasms 234Glioblastoma 233Triple Negative Breast Neoplasms 228Uterine Cervical Neoplasms 221Precursor Cell Lymphoblastic Leukemia-Lymphoma 221Lymphoma 221Sarcoma 201Hematologic Neoplasms 199Urinary Bladder Neoplasms 196Esophageal Neoplasms 190Carcinoma, Renal Cell 187Lymphoma, Non-Hodgkin 175

Interventions

capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Moderate Hepatic Impairment × 1 year × Clear all
NCT07343960 2026-05-20

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

AstraZeneca

Phase 1 Recruiting
20 enrolled

Moderate Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡